NCT07621471
IL-15 Enhanced NK Cell Therapy for Solid Tumors
StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Oct 1, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Start date changed from estimate of Oct 8, 2026 to Nov 18, 2026
- Notable Recruitment opened
- Start date: Jul 1, 2026 to Oct 8, 2026
- Eligibility criteria expanded, about 19 words
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of Dose-Limiting Toxicity (DLT)
Timeframe: Within 28 days after first infusion
Secondary (4)
Objective Response Rate (ORR)
Duration of Response (DOR)
Progression-Free Survival (PFS)
Overall Survival (OS)
Arms and interventions
IL-15 Enhanced Engineered NK CellsExperimental
Single arm. Patients receive IL-15 enhanced engineered NK cells after lymphodepletion chemotherapy.
Drugs: IL-15 enhanced engineered NK cells
Biologicals: IL-15 Enhanced Engineered NK Cells
Sites
1 site in 1 country
- Xinqiao HospitalChongqing, China